Arrowhead Pharmaceuticals Inc. (ARWR)

35.95
NASDAQ : Health Technology
Prev Close 36.60
Day Low/High 35.60 / 38.75
52 Wk Low/High 10.41 / 37.33
Avg Volume 1.33M
Exchange NASDAQ
Shares Outstanding 95.30M
Market Cap 3.49B
EPS -0.70
P/E Ratio 79.57
Div & Yield N.A. (N.A)
Arrowhead Research (ARWR) Stock Rises on Clinical Trial Results

Arrowhead Research (ARWR) Stock Rises on Clinical Trial Results

Arrowhead Research (ARWR) stock is rising on Monday, after the company announced that its Hepatitis B treatment could produce 'deep and durable reductions' of the disease's antigens and DNA.

January 2018 Options Now Available For Arrowhead Research (ARWR)

January 2018 Options Now Available For Arrowhead Research (ARWR)

Investors in Arrowhead Research Corp saw new options begin trading today, for the January 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 795 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead Late-Breaking Clinical Data Shows That ARC-520 Can Produce Deep And Durable Reductions Of Hepatitis B Viral Antigens And DNA

Arrowhead Late-Breaking Clinical Data Shows That ARC-520 Can Produce Deep And Durable Reductions Of Hepatitis B Viral Antigens And DNA

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presented data from a Phase 2a clinical study at The AASLD Liver Meeting 2015 ® demonstrating that...

Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects With ARC-520 In Hepatitis B Infected Chimpanzees

Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects With ARC-520 In Hepatitis B Infected Chimpanzees

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presents data at the AASLD Liver Meeting 2015 ® in an oral presentation and a poster showing that...

Arrowhead To Present At Upcoming Conferences

Arrowhead To Present At Upcoming Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events.

First Week Of June 2016 Options Trading For Arrowhead Research (ARWR)

First Week Of June 2016 Options Trading For Arrowhead Research (ARWR)

Investors in Arrowhead Research Corp saw new options begin trading this week, for the June 2016 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead Late-Breaker Abstract Accepted For Presentation At The AASLD Liver Meeting 2015

Arrowhead Late-Breaker Abstract Accepted For Presentation At The AASLD Liver Meeting 2015

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that additional clinical data on ARC-520, its RNAi therapeutic candidate for the treatment of...

Arrowhead Presents Overview Of Its Broad RNAi Delivery Platform And Introduces New Subcutaneously Administered Format

Arrowhead Presents Overview Of Its Broad RNAi Delivery Platform And Introduces New Subcutaneously Administered Format

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today presented an overview of its broad RNAi delivery platform at the Annual Meeting of the Oligonucleotide...

Interesting ARWR Put And Call Options For November 20th

Interesting ARWR Put And Call Options For November 20th

Investors in Arrowhead Research Corp saw new options become available this week, for the November 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new November 20th contracts and identified one put and one call contract of particular interest.

Arrowhead Research (ARWR) Showing Signs Of Perilous Reversal Today

Arrowhead Research (ARWR) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Arrowhead To Present At Upcoming Conferences

Arrowhead To Present At Upcoming Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will present at the following upcoming conferences.

Biotech Stock Mailbag: Akebia, Neuralstem, Arrowhead

Biotech Stock Mailbag: Akebia, Neuralstem, Arrowhead

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Arrowhead Research (ARWR) Marked As A Dead Cat Bounce Stock

Arrowhead Research (ARWR) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Arrowhead Research (ARWR) Stock Spikes on Positive Test Results

Arrowhead Research (ARWR) Stock Spikes on Positive Test Results

Arrowhead Research (ARWR) shares are up over 20% after releasing positive test results from its hepatitis B treatment candidate.

Trade-Ideas: Arrowhead Research (ARWR) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a pre-market mover with heavy volume candidate

Arrowhead Reports Peak Reduction In HBsAg Of Up To 99% (1.9 Log) After A Single Dose With Hepatitis B Candidate ARC-520 In Treatment Naïve Cohort Of Phase 2a Study

Arrowhead Reports Peak Reduction In HBsAg Of Up To 99% (1.9 Log) After A Single Dose With Hepatitis B Candidate ARC-520 In Treatment Naïve Cohort Of Phase 2a Study

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is hosting an analyst day today in New York, with a presentation starting at 11:00 a.

Strong On High Volume: Arrowhead Research (ARWR)

Strong On High Volume: Arrowhead Research (ARWR)

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a strong on high relative volume candidate

Arrowhead Research (ARWR) Stock: Weak On High Volume Today

Arrowhead Research (ARWR) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a weak on high relative volume candidate

Arrowhead Research (ARWR) Strong On High Relative Volume Today

Arrowhead Research (ARWR) Strong On High Relative Volume Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a strong on high relative volume candidate

Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC™ Delivery System

Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC™ Delivery System

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has nominated ARC-HIF2 as its first therapeutic candidate delivered using a new...

Arrowhead To Webcast Analyst Day Presentation On Hepatitis B Candidate ARC-520

Arrowhead To Webcast Analyst Day Presentation On Hepatitis B Candidate ARC-520

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will host an analyst day in New York on September 24, 2015, with a presentation...

Arrowhead Research (ARWR) Stock: Weak On High Volume Today

Arrowhead Research (ARWR) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a weak on high relative volume candidate

Arrowhead To Present At Jefferies 2015 Hepatitis B Summit

Arrowhead To Present At Jefferies 2015 Hepatitis B Summit

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that chief operating officer and head of R&D Bruce Given, M.

Arrowhead Reports Fiscal 2015 Third Quarter Financial Results

Arrowhead Reports Fiscal 2015 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2015 third quarter ended June 30, 2015.

Arrowhead Research is Now Oversold (ARWR)

Arrowhead Research is Now Oversold (ARWR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of ARWR December 18th Options Trading

First Week of ARWR December 18th Options Trading

Investors in Arrowhead Research Corp saw new options become available this week, for the December 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 140 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead To Report Fiscal 2015 Third Quarter Financial Results

Arrowhead To Report Fiscal 2015 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2015 third quarter ended June 30,...

Arrowhead Receives Regulatory Clearance For ARC-AAT Phase 1 In The United Kingdom And New Zealand

Arrowhead Receives Regulatory Clearance For ARC-AAT Phase 1 In The United Kingdom And New Zealand

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory permission in the United Kingdom and New Zealand to proceed with...

Arrowhead Initiates Dosing Of ARC-AAT In Patients With Alpha-1 Antitrypsin Deficiency

Arrowhead Initiates Dosing Of ARC-AAT In Patients With Alpha-1 Antitrypsin Deficiency

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it dosed the first patient in Part B of a Phase 1 clinical trial of ARC-AAT.

Today's Weak On High Volume Stock: Arrowhead Research (ARWR)

Today's Weak On High Volume Stock: Arrowhead Research (ARWR)

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a weak on high relative volume candidate

TheStreet Quant Rating: C (Hold)